Details of the Drug

General Information of Drug (ID: DMTRMBL)

Drug Name

NBI-6024

Synonyms

Diabetes therapeutics, Neurocrine/Taisho; APL (diabetes), Neurocrine/Taisho; Applied Peptide Ligand(diabetes), Neurocrine/Taisho; Insulin B9-23 peptide analog, Taisho/Neurocrine

Indication

Disease Entry	ICD 11	Status	REF
Type-1 diabetes	5A10	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Cross-matching ID

PubChem CID: 9812645
DrugBank ID: DB05819
TTD ID: D0B3MX

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin (INS)	TTZOPHG	INS_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Type-1 diabetes

ICD Disease Classification

5A10

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Insulin (INS)	DTT	INS	6.70E-01	-0.12	-0.46

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011773)
2	No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.Diabetes Care.2009 Nov;32(11):2036-40.